Company Overview

Anebulo Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and other substance-related disorders. The company operates within the biotechnology and pharmaceutical research and development industries, with no commercialized products as of the most recent publicly available filings. Its business model centers on advancing proprietary drug candidates through clinical development and, if successful, pursuing regulatory approval and commercialization.

The company’s primary asset is ANEB-001, an oral small-molecule candidate being evaluated for the treatment of acute cannabinoid intoxication. Anebulo’s strategic positioning is differentiated by its focus on an area with limited approved pharmacological treatments, targeting emergency department and acute care settings. Anebulo Pharmaceuticals was founded in 2020 and became publicly listed through an initial public offering in 2022, using the proceeds to fund clinical trials and general corporate operations.

Business Operations

Anebulo Pharmaceuticals conducts its operations as a single reportable operating segment focused on pharmaceutical research and development. Revenue generation has not yet commenced, and the company does not report product sales; operations are funded primarily through equity financing and cash reserves as disclosed in its SEC filings. Research and development expenses represent the majority of operating costs, reflecting expenditures on clinical trials, regulatory activities, and manufacturing of clinical trial materials.

The company does not maintain in-house manufacturing capabilities and relies on third-party contract research organizations and contract manufacturing organizations to conduct preclinical studies, clinical trials, and formulation work. Its operations are primarily domestic within the United States, with international activity limited to clinical or regulatory support services provided by external partners. Data inconclusive based on available public sources regarding any formal joint ventures or revenue-generating partnerships.

Strategic Position & Investments

Anebulo’s strategic direction is focused on advancing ANEB-001 through late-stage clinical development and positioning the drug for potential regulatory approval as a first-in-class treatment. Growth initiatives center on completing ongoing clinical trials, engaging with regulatory authorities, and exploring future indications related to substance intoxication or abuse disorders. The company has stated an intention to evaluate strategic collaborations or licensing opportunities, though no material agreements have been publicly confirmed.

The company has not disclosed any completed acquisitions or equity investments in other operating businesses. Its investment activity is primarily internal, allocating capital toward research and development and maintaining intellectual property protections around its lead compound. Public disclosures do not confirm involvement in additional therapeutic areas beyond cannabinoid-related conditions, and data inconclusive based on available public sources regarding expansion into other emerging biotechnology sectors.

Geographic Footprint

Anebulo Pharmaceuticals is headquartered in the United States, with corporate offices located in Texas. Its operational footprint is primarily domestic, reflecting its early-stage development status and reliance on U.S.-based clinical trial sites and service providers. The company does not report physical offices or owned facilities outside the United States.

International presence is limited to indirect engagement through third-party vendors that may operate in North America and Europe to support clinical development and regulatory compliance. The company does not report direct sales, manufacturing, or commercial infrastructure in foreign markets, and international operational influence remains minimal at this stage.

Leadership & Governance

Anebulo Pharmaceuticals is led by an executive team with experience in biotechnology, pharmaceuticals, and corporate finance. The leadership emphasizes disciplined capital allocation, regulatory rigor, and advancing clinically differentiated assets in underserved therapeutic areas. Governance is overseen by a board of directors consistent with public company requirements, as disclosed in its SEC filings.

Key executives include:

• Mark Bruzzi – Chief Executive Officer
• Thomas L. Jenkins – Chief Financial Officer
• Christopher J. Duff – Chief Operating Officer
• Michael D. Heffernan – Chief Medical Officer

The leadership team’s strategic vision centers on progressing the company’s lead program through clinical milestones while maintaining operational efficiency and compliance with public market and regulatory standards.